Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe

  Malignant Lymphoma

  Free Subscription

Articles published in Br J Dermatol

Retrieve available abstracts of 59 articles:
HTML format

Single Articles

    December 2019
  1. SUN J, Wang Y
    KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Br J Dermatol. 2019 Dec 5. doi: 10.1111/bjd.18682.

    September 2019
  2. RITCHIE S, Qureshi I, Molloy K, Yoo J, et al
    Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma at a tertiary care centre: Should we avoid chemotherapy in conditioning regimes?
    Br J Dermatol. 2019 Sep 19. doi: 10.1111/bjd.18541.
    PubMed     Abstract available

  3. ENGELINA S, Saggu M, Yoo J, Shah F, et al
    Brentuximab a novel antibody therapy: Real-World Use Confirms Efficacy and Tolerability for CD30 positive cutaneous lymphoma.
    Br J Dermatol. 2019 Sep 16. doi: 10.1111/bjd.18535.
    PubMed     Abstract available

    Health-related quality of life in cutaneous T-cell lymphoma: examining all sides of the issue.
    Br J Dermatol. 2019 Sep 2. doi: 10.1111/bjd.18428.

    August 2019
  5. BYRNE N, Hughes R, Murphy LA, Kirby B, et al
    Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin's lymphoma.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18423.
    PubMed     Abstract available

  6. ODUM N
    Deregulated signalling and inflammation in cutaneous T-cell lymphoma.
    Br J Dermatol. 2019 Aug 7. doi: 10.1111/bjd.18353.

    July 2019
  7. DOBOS G, Battistella M, Jouenne F, Mourah S, et al
    Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.
    Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328.
    PubMed     Abstract available

  8. HAO-ZE S, Liu YX, Jiang YQ, Chen SL, et al
    Clinical characteristics of primary cutaneous lymphoma: two centers analysis in China.
    Br J Dermatol. 2019 Jul 1. doi: 10.1111/bjd.18266.
    PubMed     Abstract available

    June 2019
  9. SUN J, Wang Y
    Brentuximab vedotin: unexpectedly good response in CD30(-) mycosis fungoides.
    Br J Dermatol. 2019;180:1300-1301.

    May 2019
  10. MOLLOY K, Jonak C, Sherida FJ, Woei-A-Jin H, et al
    Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Br J Dermatol. 2019 May 2. doi: 10.1111/bjd.18089.
    PubMed     Abstract available

    The emerging role of microRNAs in the molecular diagnosis of mycosis fungoides.
    Br J Dermatol. 2019;180:984-985.

  12. GELLER S, Lebowitz E, Pulitzer M, Myskowski PL, et al
    Understanding racial disparities in mycosis fungoides through international collaborative studies.
    Br J Dermatol. 2019;180:1263-1264.

  13. SCARISBRICK JJ, Quaglino P, Prince HM, Kim YH, et al
    Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease.
    Br J Dermatol. 2019;180:1264-1265.

    April 2019
  14. GOYAL A, Goyal K, Bohjanen K, Pearson D, et al
    Epidemiology of primary cutaneous gamma/delta T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the United States from 2006-2015: A Surveillance, Epidemiology, and End Results-18 analysis.
    Br J Dermatol. 2019 Apr 5. doi: 10.1111/bjd.17985.
    PubMed     Abstract available

    March 2019
  15. SEMENOV YR, Rosenberg AR, Herbosa C, Mehta-Shah N, et al
    Health-related quality of life and economic implications of cutaneous T-cell lymphoma.
    Br J Dermatol. 2019 Mar 28. doi: 10.1111/bjd.17941.
    PubMed     Abstract available

  16. WANG Y, Bagot M
    Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018.
    Br J Dermatol. 2019;180:443-444.

    February 2019
  17. DANGIEN A, Beylot-Barry M, Battistella M, Ram-Wolff C, et al
    Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin.
    Br J Dermatol. 2019 Feb 22. doi: 10.1111/bjd.17821.
    PubMed     Abstract available

  18. BONNET P, Battistella M, Roelens M, Ram-Wolff C, et al
    Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab.
    Br J Dermatol. 2019;180:419-420.

    January 2019
  19. ENZAN N, Kitadate A, Tanaka A, Matsue K, et al
    Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17603.
    PubMed     Abstract available

    December 2018
  20. GILSON D, Whittaker SJ, Child FJ, Scarisbrick JJ, et al
    British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.
    Br J Dermatol. 2018 Dec 17. doi: 10.1111/bjd.17240.

    October 2018
  21. BONNET P, Battistella M, Bouaziz JD, Ram-Wolff C, et al
    Thymic localization of erythrodermic cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17340.
    PubMed     Abstract available

  22. DESCHAMPS O, Ram-Wolff C, Beylot-Barry M, Grange F, et al
    Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma.
    Br J Dermatol. 2018 Oct 9. doi: 10.1111/bjd.17269.
    PubMed     Abstract available

  23. MIURA H
    Image Gallery: 308-nm ultraviolet B excimer laser treatment for cutaneous B-cell lymphoma nodular lesions on the face.
    Br J Dermatol. 2018;179:e166.

    September 2018
  24. DEENEN NJ, Koens L, Jaspars EH, Vermeer MH, et al
    Pitfalls in diagnosing primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
    Br J Dermatol. 2018 Sep 27. doi: 10.1111/bjd.17252.
    PubMed     Abstract available

  25. KEMPF W
    Multifocal anaplastic large cell lymphoma - insight into its biology and treatment.
    Br J Dermatol. 2018;179:565-566.

    August 2018
  26. FERTITTA L, Sicre de Fontbrune F, Battistella M, De Masson A, et al
    Folliculotropic Mycosis fungoides associated with GATA2 deficiency: a new skin manifestation.
    Br J Dermatol. 2018 Aug 12. doi: 10.1111/bjd.17081.
    PubMed     Abstract available

    July 2018
  27. CONNOLLY A, Grandi V, Stefanato CM, Palmer R, et al
    Primary cutaneous CD30(+) anaplastic large cell lymphoma associated with fingolimod.
    Br J Dermatol. 2018 Jul 14. doi: 10.1111/bjd.17003.
    PubMed     Abstract available

    May 2018
  28. CHRISTENSEN L, Cooper K, Honda K, Mansur D, et al
    Relapse rates in patients with unilesional primary cutaneous B cell lymphoma treated with radiation therapy: a single-institution experience.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16783.
    PubMed     Abstract available

    March 2018
  29. MELCHERS RC, Willemze R, Bekkenk MW, de Haas ERM, et al
    Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: Report of the Dutch Cutaneous Lymphoma Group.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16501.
    PubMed     Abstract available

    February 2018
  30. ORLOWSKA D, Selman LE, Beynon T, Radcliffe E, et al
    "It's a traumatic illness, traumatic to witness." A qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Feb 16. doi: 10.1111/bjd.16447.
    PubMed     Abstract available

    January 2018
  31. KWATRA SG, Boozalis E, Kwatra MM
    Effects of neuroimmune axis modulation by aprepitant on anti-pruritic and global disease severity in patients with cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Jan 20. doi: 10.1111/bjd.16363.
    PubMed     Abstract available

  32. MARONAS-JIMENEZ L, Ortiz-Romero PL
    Aprepitant did not modify global disease activity in cutaneous T cell lymphomas.
    Br J Dermatol. 2018 Jan 20. doi: 10.1111/bjd.16374.
    PubMed     Abstract available

  33. HURABIELLE C, Leboeuf C, Ram-Wolff C, Meignin V, et al
    KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.
    PubMed     Abstract available

    December 2017
  34. KAMSTRUP MR, Skov L, Zachariae C, Thyssen JP, et al
    Psoriasis and risk of malignant lymphoma: A population-based cohort study.
    Br J Dermatol. 2017 Dec 16. doi: 10.1111/bjd.16245.
    PubMed     Abstract available

  35. GONZALEZ-QUESADA A, Bastida J, Rivero-Vera JC, Piris-Pinilla MA, et al
    Image Gallery: Metachronic occurrence of primary cutaneous marginal zone B-cell lymphoma and primary cutaneous Rosai-Dorfman disease in the same patient.
    Br J Dermatol. 2017;177:e355.

    Brentuximab vedotin is an effective therapy for CD30(+) mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?
    Br J Dermatol. 2017;177:1474-1475.

  37. LUO Y, Liu J
    Image Gallery: Primary cutaneous precursor B-lymphoblastic lymphoma in an infant.
    Br J Dermatol. 2017;177:e353.

    November 2017
  38. MARONAS-JIMENEZ L, Estrach T, Gallardo F, Perez A, et al
    Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
    Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16128.
    PubMed     Abstract available

  39. CHEN L, Zhao X, Shi R, Zheng J, et al
    Image Gallery: Intravascular large B-cell lymphoma presenting with generalized telangiectasia.
    Br J Dermatol. 2017;177:e223.

    October 2017
  40. GELLER S, Myskowski PL, Kim YH, Moskowitz A, et al
    The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?
    Br J Dermatol. 2017 Oct 10. doi: 10.1111/bjd.16052.
    PubMed     Abstract available

    September 2017
  41. STRANZENBACH R, Dippel E, Schlaak M, Stadler R, et al
    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors.
    Br J Dermatol. 2017 Sep 10. doi: 10.1111/bjd.15972.
    PubMed     Abstract available

  42. LEWIS DJ, Kim YH, Duvic M
    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.
    Br J Dermatol. 2017 Sep 10. doi: 10.1111/bjd.15970.
    PubMed     Abstract available

  43. LIAW TY, Liang CW
    Image Gallery: Generalized annular figurate erythema as an unusual presentation of angioimmunoblastic T-cell lymphoma.
    Br J Dermatol. 2017;177:e75.

  44. TENSEN CP, Vermeer MH
    MicroRNA-155 potentiates tumour development in mycosis fungoides.
    Br J Dermatol. 2017;177:618-620.

    August 2017
  45. DE BRITO M, Gazzani P, Amel-Kashipaz R, Vydianath B, et al
    Image Gallery: Secondary cutaneous involvement of the ear with systemic small lymphocytic lymphoma: a rare manifestation.
    Br J Dermatol. 2017;177:e26.

  46. DAWE RS
    Maintenance therapy with psoralen-ultraviolet A for mycosis fungoides: in the absence of evidence sitting on the fence is appropriate.
    Br J Dermatol. 2017;177:337-338.

    Psoralen-ultraviolet A maintenance in mycosis fungoides: the underlying question.
    Br J Dermatol. 2017;177:336-337.

    July 2017
  48. BAUER WM, Aichelburg MC, Griss J, Skrabs C, et al
    Molecular Classification of Tumor Cells in a Patient with Intravascular Large B-Cell Lymphoma.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15841.
    PubMed     Abstract available

  49. STRANZENBACH R, Dippel E, Schlaak M, Stadler R, et al
    Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.
    Br J Dermatol. 2017 Jul 13. doi: 10.1111/bjd.15801.
    PubMed     Abstract available

  50. BAGOT M
    Folliculotropic mycosis fungoides is a heterogenous group.
    Br J Dermatol. 2017;177:17-18.

    June 2017
  51. LEE WJ, Kim YJ, Lee YJ, Won CH, et al
    VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
    Br J Dermatol. 2017 Jun 9. doi: 10.1111/bjd.15720.
    PubMed     Abstract available

  52. ADAMSKI H, Ingen-Housz-Oro S, Machet L, Carriou AC, et al
    Lymphomatoid papulosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma: 3 cases.
    Br J Dermatol. 2017 Jun 1. doi: 10.1111/bjd.15698.
    PubMed     Abstract available

    May 2017
    Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices.
    Br J Dermatol. 2017;176:1129-1130.

    April 2017
  54. KEMPF W
    Cutaneous lymphomas in childhood and adolescence: much needed new data.
    Br J Dermatol. 2017;176:857-858.

    August 2016
  55. GRIJSEN ML, Mtayangulwa RG, Naafs B, Jansen P, et al
    The clinical spectrum of mycosis fungoides in Tanzania, East-Africa.
    Br J Dermatol. 2016 Aug 16. doi: 10.1111/bjd.14963.
    PubMed     Abstract available

  56. KEMPF W
    TOX - what role does it play in cutaneous lymphomas?
    Br J Dermatol. 2016;175:248-9.

    Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.
    Br J Dermatol. 2016;175:246-7.

    July 2016
    Cutaneous T-cell lymphomas: an urgent need for more improved therapies.
    Br J Dermatol. 2016;175:14-5.

    May 2016
  59. LECAMWASAM K, Mathew B, Gilson D, Burton C, et al
    Correspondence article regarding CD68 as a marker of CD8+ lymphoid proliferation suggested by Wobser et al.
    Br J Dermatol. 2016;174:1158-9.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.